US OptionsDetailed Quotes
HIMS241129P43000
- 0.00
- 0.000.00%
15min DelayTrading Nov 25 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest43.00Strike Price0.00Turnover0.00%IV-45.08%PremiumNov 29, 2024Expiry Date13.36Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.32Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Hims & Hers Health Stock Discussion
Sign in to post a comment
$Hims & Hers Health (HIMS.US)$ glad i fcking bought it at sub 20 last week !
Looking forward to close abv 30 this week
This is the best stock to own now for long term growth![]()
Looking forward to close abv 30 this week
This is the best stock to own now for long term growth
5
2
$Hims & Hers Health (HIMS.US)$ want to buy but so high already
1
$Hims & Hers Health (HIMS.US)$ target 45
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Hims & Hers Health (HIMS.US)$ Still holding it but I think it's fair to say I don't understand it now.
$Hims & Hers Health (HIMS.US)$
up nearly 4% in overnight trading following Trump’s nomination of Marty Makary as Head of the FDA.
Dr. Makary currently serves as the Chief Medical Officer of Sesame, a telehealth platform that also offers compounded versions of GLP-1s.
up nearly 4% in overnight trading following Trump’s nomination of Marty Makary as Head of the FDA.
Dr. Makary currently serves as the Chief Medical Officer of Sesame, a telehealth platform that also offers compounded versions of GLP-1s.
$Hims & Hers Health (HIMS.US)$ started my 1st position last week at 19.60. I first spoted this when it hit new ATH at 30 but was big sell off on Amzn news. It was a blessing. Last week i was up +30%. And we stop at previous high at 25.
Pre market is 26.35 +3.6%. Strong start to potentially revisit 30 this week.
Pre market is 26.35 +3.6%. Strong start to potentially revisit 30 this week.
2
1
$Hims & Hers Health (HIMS.US)$ Trageg 45 based on cup and handle pattern.
2
Bullish Report on HIMS (Hims & Hers Health Inc.)
Overview
Hims & Hers Health (HIMS) has been a standout performer in 2024, delivering an impressive 194.94% year-to-date return. The company has demonstrated significant growth momentum, driven by strong fundamentals and increasing investor confidence. The recent technical breakout highlights continued upside potential for the stock.
Current Price Analysis
• Current Price (Nov 22, 2024): $25.33
• Daily Change: +$1.18 (+4.89%)
• Post-Mar...
Overview
Hims & Hers Health (HIMS) has been a standout performer in 2024, delivering an impressive 194.94% year-to-date return. The company has demonstrated significant growth momentum, driven by strong fundamentals and increasing investor confidence. The recent technical breakout highlights continued upside potential for the stock.
Current Price Analysis
• Current Price (Nov 22, 2024): $25.33
• Daily Change: +$1.18 (+4.89%)
• Post-Mar...
7
$XPeng (XPEV.US)$ | Bernstein analyst Eunice Lee maintains XPeng with a hold rating, and adjusts the target price from $9 to $14.
$CrowdStrike (CRWD.US)$ | Stifel analyst Adam Borg maintains CrowdStrike Holdings with a Buy and raises the price target from $300 to $375.
$Alibaba (BABA.US)$ | Barclays analyst Jiong Shao maintains Alibaba with a buy rating, and adjusts the target price from $137 to $130.
$Robinhood (HOOD.US)$ | Bernstein analyst Gautam Chhugani maintain...
$CrowdStrike (CRWD.US)$ | Stifel analyst Adam Borg maintains CrowdStrike Holdings with a Buy and raises the price target from $300 to $375.
$Alibaba (BABA.US)$ | Barclays analyst Jiong Shao maintains Alibaba with a buy rating, and adjusts the target price from $137 to $130.
$Robinhood (HOOD.US)$ | Bernstein analyst Gautam Chhugani maintain...
3
No comment yet
104837679 : Lucky you! Sadly no funds for me :(
Ser7 : I love this stock too